Paige Prostate, is the first artificial intelligence (AI)-based software designed to identify an area of interest on the prostate biopsy image with the highest likelihood of harboring cancer so it can be reviewed further by the pathologist if the area of concern has not been identified on initial review.

September 22, 2021 — The U.S. Food and Drug Administration authorized marketing of software to assist medical professionals who examine body tissues (pathologists) in the detection of areas that are suspicious for cancer as an adjunct (supplement) to the review of digitally-scanned slide images from prostate biopsies (tissue removed from the body). The software, called Paige Prostate, is the first artificial intelligence (AI)-based software designed to identify an area of interest on the prostate biopsy image with the highest likelihood of harboring cancer so it can be reviewed further by the pathologist if the area of concern has not been identified on initial review.

“Pathologists examine biopsies of tissue suspected for diseases, such as prostate cancer, every day. Identifying areas of concern on the biopsy image can help pathologists make a diagnosis that informs the appropriate treatment,” said Tim Stenzel, M.D., Ph.D., director of the Office of In Vitro Diagnostics and Radiological Health in the FDA’s Center for Devices and Radiological Health. “The authorization of this AI-based software can help increase the number of identified prostate biopsy samples with cancerous tissue, which can ultimately save lives.”

Cancer that starts in the prostate is called prostate cancer. According to the Centers for Disease Control and Prevention, aside from non-melanoma skin cancer, prostate cancer is the most common cancer among men in the United States. It is also one of the leading causes of cancer death among men.

Paige Prostate is compatible for use with slide images that have been digitized using a scanner. The digitized slide image can then be visualized using a slide image viewer.

The FDA evaluated data from a clinical study where 16 pathologists examined 527 slide images of prostate biopsies (171 cancer and 356 benign) that were digitized using a scanner. For each slide image, each pathologist completed two assessments, one without Paige Prostate’s assistance (unassisted read) and one with Paige Prostate’s assistance (assisted read). While the clinical study did not evaluate the impact on final patient diagnosis, which is typically based on multiple biopsies, the study found that Paige Prostate improved detection of cancer on individual slide images by 7.3% on average when compared to pathologists’ unassisted reads for whole slide images of individual biopsies, with no impact on the read of benign slide images.

Potential risks include false negative and false positive results, which is mitigated by the device’s use as an adjunct (e.g., the device assists pathologists reviewing slide images) and by the professional evaluation by a qualified pathologist who takes into account patient history among other relevant clinical information, and who may perform additional laboratory studies on the samples prior to rendering a final diagnosis.

The FDA reviewed the device through the De Novo premarket review pathway, a regulatory pathway for low- to moderate-risk devices of a new type. Along with this authorization, the FDA is establishing special controls for devices of this type, including requirements related to labeling and performance testing. When met, the special controls, along with general controls, provide reasonable assurance of safety and effectiveness for devices of this type. This action creates a new regulatory classification, which means that subsequent devices of the same type with the same intended use may go through FDA’s 510(k) premarket process, whereby devices can obtain marketing authorization by demonstrating substantial equivalence to a predicate device.

The FDA granted marketing authorization of the Paige Prostate software to Paige.AI.

For more information: www.fda.gov

Related Content

Feature | Radiology Business | By Melinda Taschetta-Millane

Here is what you and your colleagues found to be most interesting in the field of medical imaging during the month of ...

Time August 01, 2022
arrow
News | RSNA

July 29, 2022 — The Radiological Society of North America (RSNA), in collaboration with the American Society of ...

Time July 29, 2022
arrow
News | Magnetic Resonance Imaging (MRI)

July 27, 2022 — Viz.ai, a leading AI-powered disease detection and intelligent care coordination platform, announced it ...

Time July 27, 2022
arrow
News | Artificial Intelligence

July 26, 2022 — Aidoc, a leading provider of AI healthcare solutions, today announced a partnership with UofL Health, a ...

Time July 26, 2022
arrow
News | Oncology Information Management Systems (OIMS)

July 26, 2022 — The oncology information system market is expected to expand at a 7.8% CAGR. The oncology information ...

Time July 26, 2022
arrow
News | Computed Tomography (CT)

July 21, 2022 — According to ARRS’ American Journal of Roentgenology (AJR), an AI tool for detection of incidental ...

Time July 22, 2022
arrow
News | PET Imaging

July 20, 2022 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization ...

Time July 20, 2022
arrow
News | Digital Radiography (DR)

July 15, 2022 — Mike Cairnie, MinXray’s Director of Global Sales, and a group of three medical professionals from Qure ...

Time July 15, 2022
arrow
Feature | Radiology Business | By Merilee Kern, MBA

Numerous indicators make clear that the next five years will usher in extreme transformation for a multitude of ...

Time July 07, 2022
arrow
Feature | Treatment Planning | Information provided by Grand View Research

The global treatment planning systems and advanced image processing market size was valued at USD 1.7 billion in 2021 ...

Time July 07, 2022
arrow
Subscribe Now